Global Oligonucleotide Synthesis Market Size to Reach $24.1 Billion at a CAGR of 16.1% by 2030

The Global Oligonucleotide Synthesis Market size reached USD 7.3 Billion in 2022. Vantage Market Research expects the market to reach USD 24.1 Billion by 2030, exhibiting a growth rate (CAGR) of 16.1% during 2024-2030.

Table of Contents

Introduction

Oligonucleotide Synthesis, single-stranded DNA molecules with precise sequences, has evolved and undergone a revolution. From its inception as a manual, labor-intensive process, this technique has metamorphosed into a sophisticated, automated marvel that traverses the realms of basic research to ground-breaking therapies. This comprehensive exploration unravels the changing landscape of Oligonucleotide Synthesis, encapsulating its applications, trends, advancements, and future promises. The market is predicted to be valued at USD 24.1 billion by 2030, with an exponential growth of 16.1% in the next seven years.

Request Sample Report of Oligonucleotide Synthesis Market @ https://www.vantagemarketresearch.com/oligonucleotide-synthesis-market-2366/request-sample

Top Companies in Global Oligonucleotide Synthesis Market

• Agilent Technologies Inc. (U.S.)
• Atdbio Ltd. (UK)
• Kaneka Eurogentec S.A. (Belgium)
• General Electric (U.S.)
• Genscript (U.S.)
• LGC Limited (UK)
• Bio-Synthesis Inc. (U.S.)
• Eurofins Genomics (Luxembourg)
• Ajinomoto Co. Inc. (Japan)
• Danaher Corp. (U.S.) 

Applications Unveiled

The significance of Oligonucleotide Synthesis lies in its ability to craft custom DNA oligos with specific sequences, expanding its applications across diverse life sciences domains. These custom oligos serve as indispensable probes for detecting specific DNA sequences or as primers for the ubiquitous polymerase chain reaction (PCR), amplifying targeted DNA regions. Additionally, the synthesis of artificial genes, the development of antisense oligonucleotides (with several siRNAs in clinical development), and the creation of tools for introducing targeted genetic mutations showcase the versatility of this revolutionary technique.

Evolutionary Trends

Historically, the manual synthesis of oligonucleotides prevailed until the advent of automated methods. Traditional methods involved solutions or solid-phase supports using glass columns with porous filters. However, the landscape has transformed with contemporary Oligonucleotide Synthesis predominantly occurring on solid-phase supports using computer-controlled instruments. The column format, ideal for research and large-scale applications, is collated with the multi-well plate format, specifically designed for high-throughput synthesis on a smaller scale. Commercially available synthesizers cater to various synthesis scales, depicting the industry's dynamic evolution.

Advancements Paving the Way

Recent years have witnessed monumental advancements in Oligonucleotide Synthesis chemistries, purification, and quality control technologies. This has resulted in enhanced quality and yield and substantial cost reductions. Simultaneously, developments in oligonucleotide applications have catalysed a dramatic expansion of available modifications. These technological strides have ushered in an era of high-throughput manufacturing, exemplified by pioneers like Integrated DNA Technologies.

Future Horizons

The ability to synthesize small, synthetic DNA pieces with defined sequences has unleashed unprecedented possibilities. From personalized medicine and gene editing to gene regulation, the future of Oligonucleotide Synthesis is poised for continual expansion, ushering in novel and impactful applications. Innovations may lead to a greater focus on personalized medicine, coupled with CRISPR-Cas9, introducing changes in specific genes or RNA transcripts associated with various diseases. Tailoring therapies to individual needs by designing oligonucleotides targeting particular mutations or genomic regions is on the horizon.

DNA oligonucleotides are positioned as key factor in developing new tools, allowing researchers to delve deeper into gene function and regulation. By synthesizing oligonucleotides that mimic specific regulatory elements such as promoter or enhancer regions, scientists gain profound insights into how genes are regulated and contribute to diseases.

Buy Now Our Oligonucleotide Synthesis Industry Report @ https://www.vantagemarketresearch.com/buy-now/oligonucleotide-synthesis-market-2366/0

Revolution in Production

A significant breakthrough has been achieved in the realm of oligonucleotide therapeutics. Scientists at The University of Manchester have developed a sustainable and scalable approach to produce life-saving oligonucleotide therapeutics on a large scale, ensuring high purity and minimal environmental impact. This breakthrough addresses the challenges associated with current methods, including large amounts of solvent usage, substantial waste generation, and low yield and modest purity of final products. 

The ground-breaking approach utilizes enzymes called polymerases to amplify a catalytic DNA template, allowing the high-volume production of therapeutic oligonucleotides in a single step. This contrasts with established methods involving iterative rounds of chain extension, capping, oxidation, and deprotection. Collaborative efforts with technology innovators and pharmaceutical companies aim to scale up this approach, promising a significant impact on the pharmaceutical industry. 

Industry Initiatives and Investments

The Oligonucleotide Synthesis landscape is witnessing a surge in industry initiatives and investments, reflecting this revolutionary technology's growing demand and potential. In April 2021, ATDBio secured funding for the rapid, efficient, and automatable production of oligonucleotides for COVID-19 testing, emphasizing the industry's responsiveness to global health challenges.

North America is emerging as a hotspot for academic, industrial, biotech, and pharmaceutical laboratories requiring oligonucleotides for research and development. Companies like ABC Biotech are investing in state-of-the-art synthesis facilities to meet the demand driven by collaborations with academic institutions and pharmaceutical companies. 

Major players, including Agilent Technologies, are earmarking substantial investments to expand manufacturing capacities for therapeutic nucleic acids or oligonucleotides. Agilent's strategic move aims to meet the escalating demand for siRNA, antisense molecules, and CRISPR-guided RNA programs.

Pharmaceutical Landscape

Large pharmaceutical companies, including Vertex Pharmaceuticals and GSK, are recognizing the potential of oligonucleotide therapies. Agreements and investments amounting to hundreds of millions signify the industry's acknowledgment of the transformative impact of oligonucleotides in drug development. The approval of 15 oligonucleotide drugs by the US Food and Drug Administration as of 2022, along with over 246 ongoing clinical trials, showcases this evolving landscape's robust and dynamic nature.

Conclusion

The landscape of Oligonucleotide Synthesis has shifted from manual craftsmanship to automated precision, shaping a future replete with possibilities. The applications, trends, and advancements discussed underscore the transformative impact of Oligonucleotide Synthesis in research, therapeutics, and beyond. As the industry witnesses unprecedented investments, breakthroughs, and collaborations, Oligonucleotide Synthesis stands at the forefront of scientific innovation, promising a future where tailored therapies and ground-breaking discoveries are not just aspirations but tangible realities. The journey continues, and the landscape of Oligonucleotide Synthesis is poised for an exciting and transformative future.

Read Our Latest Press Release: Paper Packaging Market - In-depth Analysis

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: [email protected]

Website: Vantage Market Research